A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009877/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and
maintaining testosterone suppression (<50 ng/dL).
提供机构：
Vivli
创建时间：
2024-03-14
